These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 20524091

  • 1. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
    Elliott WJ.
    Curr Hypertens Rep; 2010 Aug; 12(4):258-66. PubMed ID: 20524091
    [Abstract] [Full Text] [Related]

  • 2. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.
    Cochrane Database Syst Rev; 2014 Oct 23; 2014(10):CD007744. PubMed ID: 25340915
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec 23; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

  • 4. Clinical use and pharmacological properties of selective COX-2 inhibitors.
    Shi S, Klotz U.
    Eur J Clin Pharmacol; 2008 Mar 23; 64(3):233-52. PubMed ID: 17999057
    [Abstract] [Full Text] [Related]

  • 5. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC, Ashcroft DM.
    Pharmacoepidemiol Drug Saf; 2007 Jul 23; 16(7):762-72. PubMed ID: 17457957
    [Abstract] [Full Text] [Related]

  • 6. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.
    Rheumatology (Oxford); 2007 Mar 27; 46(3):496-507. PubMed ID: 16936327
    [Abstract] [Full Text] [Related]

  • 8. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP, Deray G, Héloire F.
    Presse Med; 2006 Sep 27; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
    McGettigan P, Henry D.
    JAMA; 2006 Oct 04; 296(13):1633-44. PubMed ID: 16968831
    [Abstract] [Full Text] [Related]

  • 10. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec 04; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 11. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
    Cunnington M, Webb D, Qizilbash N, Blum D, Mander A, Funk MJ, Weil J.
    Pharmacoepidemiol Drug Saf; 2008 Jun 04; 17(6):601-8. PubMed ID: 18383442
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 13. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
    Kristensen LE, Jakobsen AK, Askling J, Nilsson F, Jacobsson LT.
    Arthritis Care Res (Hoboken); 2015 Aug 18; 67(8):1137-49. PubMed ID: 25623277
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular effects of cyclooxygenase-2 inhibitors.
    Brophy JM.
    Curr Opin Gastroenterol; 2007 Nov 18; 23(6):617-24. PubMed ID: 17906437
    [Abstract] [Full Text] [Related]

  • 15. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
    Andersohn F, Schade R, Suissa S, Garbe E.
    Stroke; 2006 Jul 18; 37(7):1725-30. PubMed ID: 16728684
    [Abstract] [Full Text] [Related]

  • 16. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 18; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 17. The COX-2 inhibitors--an update.
    Furberg CD.
    Am Heart J; 2006 Aug 18; 152(2):197-9. PubMed ID: 16875896
    [No Abstract] [Full Text] [Related]

  • 18. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
    Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CP.
    Cardiovasc Ther; 2012 Dec 18; 30(6):342-50. PubMed ID: 21884017
    [Abstract] [Full Text] [Related]

  • 19. Coxibs: can this class of drugs survive?
    Tabrizchi R.
    Vasc Health Risk Manag; 2005 Dec 18; 1(1):5-8. PubMed ID: 17319092
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
    Baraf HS.
    Curr Pharm Des; 2007 Dec 18; 13(22):2228-36. PubMed ID: 17691996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.